GSK Initiates First-Time-in-Human Study of Remzistotug for Advanced Solid Tumors
GlaxoSmithKline has launched a first-time-in-human study of remzistotug targeting advanced solid tumors.
Asset / Drug
Drug and asset intelligence for Remzistotug with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.